letrozole has been researched along with Lymph Node Metastasis in 35 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer." | 9.30 | Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. ( Abdi, E; Aebi, S; Barbeaux, A; Bernhard, J; Biganzoli, L; Chirgwin, J; Coates, AS; Colleoni, M; Di Lauro, V; Di Leo, A; Foukakis, T; Francis, PA; Gelber, RD; Goldhirsch, A; Gomez, HL; Graas, MP; Graiff, C; Jerusalem, G; Karlsson, P; Luo, W; Maibach, R; Müller, B; Neven, P; Pagani, O; Rabaglio, M; Regan, MM; Ribi, K; Ruhstaller, T; Vorobiof, D, 2019) |
| "The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 9.27 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. ( Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS, 2018) |
| "Forty postmenopausal women with non-metastatic ER-positive, HER2-negative invasive breast cancer with a primary tumor > 2 cm or positive axillary lymph node(s) proved by biopsy will be randomly (1:1) enrolled from Sun Yat-Sen Memorial Hospital to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles before surgery." | 9.24 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. ( Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N, 2017) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 9.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years." | 9.11 | Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2005) |
| " Palbociclib with letrozole may be a good treatment in the preoperative stage for luminal breast cancer that is resistant to chemotherapy." | 8.02 | Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report. ( Choi, JH; Jeon, CW; Jung, M; Jung, SU, 2021) |
| "Eligible women were 18 years or older and postmenopausal with diagnosed metastatic HR-positive, HER2-negative breast cancer and were suitable candidates for letrozole therapy." | 7.88 | Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. ( Brufsky, AM; Cotter, MJ; Dequen, F; Joy, AA; Lu, DR; Stearns, V; Verma, S, 2018) |
| " We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)." | 7.76 | Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. ( Caravelli, JF; Dang, C; Dickler, MN; Flombaum, CD; Fornier, M; Geneus, S; Grothusen, J; Hudis, CA; Lake, D; Melisko, ME; Norton, L; Park, JW; Patil, S; Paulson, M; Robson, M; Rugo, HS; Seidman, AD; Theodoulou, M; Traina, TA; Yeh, B, 2010) |
| "We report a breast cancer patient with leptomeningeal carcinomatosis (LM) who showed an excellent objective and subjective response to letrozole, with a progression-free survival of 16 months." | 7.72 | Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. ( Artac, M; Bozcuk, HS; Ozdogan, M; Sagtas, E; Samur, M; Savas, B; Yildiz, M, 2003) |
| "We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors." | 6.82 | Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. ( Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW, 2016) |
| "Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women (median (range): 67." | 6.73 | Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( Bastert, G; Jänicke, F; Kiesel, L; Krainick-Strobel, UE; Lichtenegger, W; Paepke, S; Tulusan, AH; Wackwitz, B; Wallwiener, D, 2008) |
| "Women with breast cancer and diabetes mellitus (DM) have poorer survival." | 5.43 | Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. ( Booth, CM; Eisenhauer, EA; Goodwin, RA; Goss, PE; Jamal, R; Shepherd, LE; Tu, D, 2016) |
| "In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer." | 5.30 | Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. ( Abdi, E; Aebi, S; Barbeaux, A; Bernhard, J; Biganzoli, L; Chirgwin, J; Coates, AS; Colleoni, M; Di Lauro, V; Di Leo, A; Foukakis, T; Francis, PA; Gelber, RD; Goldhirsch, A; Gomez, HL; Graas, MP; Graiff, C; Jerusalem, G; Karlsson, P; Luo, W; Maibach, R; Müller, B; Neven, P; Pagani, O; Rabaglio, M; Regan, MM; Ribi, K; Ruhstaller, T; Vorobiof, D, 2019) |
| "The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 5.27 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. ( Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS, 2018) |
| "Forty postmenopausal women with non-metastatic ER-positive, HER2-negative invasive breast cancer with a primary tumor > 2 cm or positive axillary lymph node(s) proved by biopsy will be randomly (1:1) enrolled from Sun Yat-Sen Memorial Hospital to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles before surgery." | 5.24 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. ( Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N, 2017) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 5.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "Third-generation nonsteroidal aromatase inhibitors (AIs), letrozole and anastrozole, are superior to tamoxifen as initial therapy for early breast cancer but have not been directly compared in a head-to-head adjuvant trial." | 5.12 | A decade of letrozole: FACE. ( O'Shaughnessy, J, 2007) |
| "Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years." | 5.11 | Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2005) |
| "Patients with all stages of primary breast cancer are at continuing risk of relapse following 5 years of adjuvant tamoxifen therapy, even in the absence of lymph node involvement." | 4.83 | Extended adjuvant therapy with letrozole: reducing the risk of recurrence. ( Dixon, JM, 2006) |
| "The patient received hormone therapy using letrozole based on a clinical diagnosis of occult breast cancer with peritoneal dissemination and right axillary lymph node metastasis." | 4.02 | Long-term response on letrozole for gastric cancer: A case report. ( Hiramatsu, T; Hongo, K; Iida, Y; Ishihara, Y; Kita, Y; Kobayashi, R; Kuriki, K; Onoda, T; Takabayashi, N, 2021) |
| " Palbociclib with letrozole may be a good treatment in the preoperative stage for luminal breast cancer that is resistant to chemotherapy." | 4.02 | Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report. ( Choi, JH; Jeon, CW; Jung, M; Jung, SU, 2021) |
| "Eligible women were 18 years or older and postmenopausal with diagnosed metastatic HR-positive, HER2-negative breast cancer and were suitable candidates for letrozole therapy." | 3.88 | Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. ( Brufsky, AM; Cotter, MJ; Dequen, F; Joy, AA; Lu, DR; Stearns, V; Verma, S, 2018) |
| " We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)." | 3.76 | Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. ( Caravelli, JF; Dang, C; Dickler, MN; Flombaum, CD; Fornier, M; Geneus, S; Grothusen, J; Hudis, CA; Lake, D; Melisko, ME; Norton, L; Park, JW; Patil, S; Paulson, M; Robson, M; Rugo, HS; Seidman, AD; Theodoulou, M; Traina, TA; Yeh, B, 2010) |
| "Tumors from 228 postmenopausal women with confirmed ER+ stage 2 and 3 breast cancers in the P024 neoadjuvant endocrine therapy trial, which compared letrozole and tamoxifen for 4 months before surgery, were analyzed for posttreatment ER status, Ki67 proliferation index, histological grade, pathological tumor size, node status, and treatment response." | 3.74 | Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. ( A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A, 2008) |
| "The steroidal aromatase inactivator exemestane has demonstrated activity after prior failure of non-steroidal aromatase inhibitors (including third-generation inhibitors letrozole and anastrozole) in postmenopausal women with advanced breast cancer." | 3.73 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. ( Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F, 2005) |
| "We report a breast cancer patient with leptomeningeal carcinomatosis (LM) who showed an excellent objective and subjective response to letrozole, with a progression-free survival of 16 months." | 3.72 | Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. ( Artac, M; Bozcuk, HS; Ozdogan, M; Sagtas, E; Samur, M; Savas, B; Yildiz, M, 2003) |
| "We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors." | 2.82 | Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. ( Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW, 2016) |
| "Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women (median (range): 67." | 2.73 | Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( Bastert, G; Jänicke, F; Kiesel, L; Krainick-Strobel, UE; Lichtenegger, W; Paepke, S; Tulusan, AH; Wackwitz, B; Wallwiener, D, 2008) |
| "Metastases of breast carcinoma to the main bronchus and choroid are rare, but have been reported in relevant literature." | 1.48 | Late distant recurrence of breast carcinoma and metastasis to the main bronchus and choroid: A case report. ( Cai, Q; Fu, S; Luo, Z; Wang, X; Zhai, L; Zhao, Y, 2018) |
| "Applying STEPP to data from a breast cancer treatment trial with multiple markers, we found that none of the three benefit functions identified a promising subgroup for further study." | 1.43 | Evaluating Markers for Guiding Treatment. ( Baker, SG; Bonetti, M, 2016) |
| "Women with breast cancer and diabetes mellitus (DM) have poorer survival." | 1.43 | Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. ( Booth, CM; Eisenhauer, EA; Goodwin, RA; Goss, PE; Jamal, R; Shepherd, LE; Tu, D, 2016) |
| "106 patients treated for breast cancer at Southampton University Hospital with PHT without surgery were identified (Mean age 84." | 1.42 | Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma. ( Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C, 2015) |
| "The median interval from diagnosis of breast cancer was 57 months (range: 11 - 189 mo)." | 1.38 | [Endobronchial metastases from breast cancer: a clinicopathological and survival analysis]. ( Cai, RG; Fan, Y; Li, J; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (45.71) | 29.6817 |
| 2010's | 16 (45.71) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Leone, JP | 1 |
| Cole, BF | 1 |
| Regan, MM | 2 |
| Thürlimann, B | 1 |
| Coates, AS | 2 |
| Rabaglio, M | 2 |
| Giobbie-Hurder, A | 1 |
| Gelber, RD | 2 |
| Ejlertsen, B | 2 |
| Harvey, VJ | 1 |
| Neven, P | 2 |
| Láng, I | 1 |
| Bonnefoi, H | 1 |
| Wardley, A | 1 |
| Goldhirsch, A | 2 |
| Di Leo, A | 2 |
| Colleoni, M | 2 |
| Vaz-Luis, I | 1 |
| Lin, NU | 1 |
| Jung, SU | 1 |
| Jung, M | 1 |
| Choi, JH | 1 |
| Jeon, CW | 1 |
| Iida, Y | 1 |
| Hongo, K | 1 |
| Onoda, T | 1 |
| Kita, Y | 1 |
| Ishihara, Y | 1 |
| Takabayashi, N | 1 |
| Kobayashi, R | 1 |
| Kuriki, K | 1 |
| Hiramatsu, T | 1 |
| Martin-Romano, P | 1 |
| Jurado, M | 1 |
| Idoate, MA | 1 |
| Arbea, L | 1 |
| Hernandez-Lizoain, JL | 1 |
| Cano, D | 1 |
| Paramo, JA | 1 |
| Martin-Algarra, S | 1 |
| Wu, W | 1 |
| Deng, H | 1 |
| Rao, N | 1 |
| You, N | 1 |
| Yang, Y | 1 |
| Cao, M | 1 |
| Liu, J | 1 |
| Hortobagyi, GN | 2 |
| Stemmer, SM | 1 |
| Burris, HA | 1 |
| Yap, YS | 1 |
| Sonke, GS | 1 |
| Paluch-Shimon, S | 1 |
| Campone, M | 1 |
| Petrakova, K | 1 |
| Blackwell, KL | 1 |
| Winer, EP | 1 |
| Janni, W | 1 |
| Verma, S | 2 |
| Conte, P | 1 |
| Arteaga, CL | 1 |
| Cameron, DA | 3 |
| Mondal, S | 1 |
| Su, F | 1 |
| Miller, M | 1 |
| Elmeliegy, M | 1 |
| Germa, C | 1 |
| O'Shaughnessy, J | 3 |
| Luo, Z | 1 |
| Cai, Q | 1 |
| Zhao, Y | 1 |
| Wang, X | 1 |
| Fu, S | 1 |
| Zhai, L | 1 |
| Stearns, V | 1 |
| Brufsky, AM | 1 |
| Cotter, MJ | 1 |
| Lu, DR | 1 |
| Dequen, F | 1 |
| Joy, AA | 1 |
| Ribi, K | 1 |
| Luo, W | 1 |
| Karlsson, P | 1 |
| Chirgwin, J | 1 |
| Aebi, S | 1 |
| Jerusalem, G | 1 |
| Di Lauro, V | 1 |
| Gomez, HL | 1 |
| Ruhstaller, T | 1 |
| Abdi, E | 1 |
| Biganzoli, L | 1 |
| Müller, B | 1 |
| Barbeaux, A | 1 |
| Graas, MP | 1 |
| Francis, PA | 1 |
| Foukakis, T | 1 |
| Pagani, O | 1 |
| Graiff, C | 1 |
| Vorobiof, D | 1 |
| Maibach, R | 1 |
| Bernhard, J | 1 |
| Rimawi, MF | 1 |
| Mayer, IA | 1 |
| Forero, A | 1 |
| Nanda, R | 1 |
| Goetz, MP | 2 |
| Rodriguez, AA | 1 |
| Pavlick, AC | 1 |
| Wang, T | 1 |
| Hilsenbeck, SG | 1 |
| Gutierrez, C | 1 |
| Schiff, R | 1 |
| Osborne, CK | 1 |
| Chang, JC | 1 |
| Layfield, DM | 1 |
| Mohamud, M | 1 |
| Odofin, O | 1 |
| Walsh, C | 1 |
| Royle, GT | 1 |
| Cutress, RI | 1 |
| Pagano, M | 1 |
| Asensio, SN | 1 |
| Zanelli, F | 1 |
| Lococo, F | 1 |
| Cavazza, A | 1 |
| Damiani, S | 1 |
| Rapicetta, C | 1 |
| Gnoni, R | 1 |
| Boni, C | 1 |
| Tan, WW | 1 |
| Allred, JB | 1 |
| Moreno-Aspitia, A | 1 |
| Northfelt, DW | 1 |
| Ingle, JN | 3 |
| Perez, EA | 3 |
| Goodwin, RA | 1 |
| Jamal, R | 1 |
| Booth, CM | 1 |
| Goss, PE | 3 |
| Eisenhauer, EA | 1 |
| Tu, D | 3 |
| Shepherd, LE | 3 |
| Baker, SG | 1 |
| Bonetti, M | 1 |
| Smith, I | 2 |
| Yardley, D | 1 |
| Burris, H | 1 |
| De Boer, R | 1 |
| Amadori, D | 1 |
| McIntyre, K | 1 |
| Gnant, M | 1 |
| Jonat, W | 2 |
| Pritchard, KI | 3 |
| Dowsett, M | 3 |
| Hart, L | 1 |
| Poggio, S | 1 |
| Comarella, L | 1 |
| Salomon, H | 1 |
| Wamil, B | 1 |
| Nagykálnai, T | 1 |
| Ellis, MJ | 1 |
| Tao, Y | 1 |
| Luo, J | 1 |
| A'Hern, R | 1 |
| Evans, DB | 1 |
| Bhatnagar, AS | 1 |
| Chaudri Ross, HA | 1 |
| von Kameke, A | 1 |
| Miller, WR | 1 |
| Eiermann, W | 1 |
| Cianfrocca, M | 1 |
| Traina, TA | 1 |
| Rugo, HS | 1 |
| Caravelli, JF | 1 |
| Patil, S | 1 |
| Yeh, B | 1 |
| Melisko, ME | 1 |
| Park, JW | 1 |
| Geneus, S | 1 |
| Paulson, M | 1 |
| Grothusen, J | 1 |
| Seidman, AD | 1 |
| Fornier, M | 1 |
| Lake, D | 1 |
| Dang, C | 1 |
| Robson, M | 1 |
| Theodoulou, M | 1 |
| Flombaum, CD | 1 |
| Norton, L | 3 |
| Hudis, CA | 1 |
| Dickler, MN | 1 |
| Jang, KS | 1 |
| Lee, WM | 1 |
| Kim, YJ | 1 |
| Cho, SH | 1 |
| Li, J | 1 |
| Xu, BH | 1 |
| Wang, JY | 1 |
| Li, Q | 2 |
| Zhang, P | 1 |
| Yuan, P | 1 |
| Ma, F | 1 |
| Fan, Y | 1 |
| Cai, RG | 1 |
| Ozdogan, M | 1 |
| Samur, M | 1 |
| Bozcuk, HS | 1 |
| Sagtas, E | 1 |
| Yildiz, M | 1 |
| Artac, M | 1 |
| Savas, B | 1 |
| Martino, S | 2 |
| Robert, NJ | 2 |
| Muss, HB | 2 |
| Piccart, MJ | 2 |
| Castiglione, M | 2 |
| Livingston, RB | 2 |
| Davidson, NE | 2 |
| Abrams, JS | 2 |
| Palmer, MJ | 2 |
| Pater, JL | 2 |
| Bertelli, G | 1 |
| Garrone, O | 1 |
| Merlano, M | 1 |
| Occelli, M | 1 |
| Bertolotti, L | 1 |
| Castiglione, F | 1 |
| Pepi, F | 1 |
| Fusco, O | 1 |
| Del Mastro, L | 1 |
| Leonard, RC | 1 |
| Erban, JK | 1 |
| Dixon, JM | 1 |
| Giordano, SH | 1 |
| Mundhenke, C | 1 |
| Arriola, E | 1 |
| Hui, E | 1 |
| Smith, IE | 1 |
| Krainick-Strobel, UE | 1 |
| Lichtenegger, W | 1 |
| Wallwiener, D | 1 |
| Tulusan, AH | 1 |
| Jänicke, F | 1 |
| Bastert, G | 1 |
| Kiesel, L | 1 |
| Wackwitz, B | 1 |
| Paepke, S | 1 |
| Goyal, S | 1 |
| Puri, T | 1 |
| Julka, PK | 1 |
| Rath, GK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| A Randomised Pilot Study of Neoadjuvant Everolimus Plus Letrozole Compared With FEC in Postmenopausal Patients With ER-positive, HER2-negative Breast Cancer[NCT02742051] | Phase 2 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease[NCT01958021] | Phase 3 | 668 participants (Actual) | Interventional | 2013-12-17 | Completed | ||
| Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.[NCT05163106] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-12-01 | Recruiting | ||
| Phase II, Multicenter, Single Arm Trial to Assess the Feasibility of First Line Ribociclib in Combination With a Non Steroidal Aromatase Inhibitor in Elderly Patients With Hormone Receptor Positive/HER2 Negative Advanced Breast Cancer[NCT03944434] | Phase 2 | 116 participants (Actual) | Interventional | 2018-12-27 | Active, not recruiting | ||
| A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)[NCT00651456] | Phase 2/Phase 3 | 448 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer[NCT01973660] | Phase 2 | 151 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477] | Phase 2 | 257 participants (Actual) | Interventional | 2017-10-05 | Active, not recruiting | ||
| A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients[NCT00548184] | Phase 2 | 65 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer[NCT01105312] | Phase 1/Phase 2 | 28 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665] | 71 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer[NCT00305825] | Phase 2 | 43 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer[NCT03917082] | Phase 2 | 290 participants (Anticipated) | Interventional | 2019-09-23 | Active, not recruiting | ||
| A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen[NCT00003140] | Phase 3 | 5,187 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| Pre-operative Hormone Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer: An Uncontrolled Phase IIb/III Trial to Assess Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate [NCT00535418] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall response rate (ORR) is defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1. CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. (NCT01958021)
Timeframe: Up to approximately 20 months
| Intervention | percentage of participants (Number) |
|---|---|
| LEE011 + Letrozole | 40.7 |
| Placebo + Letrozole | 27.5 |
PFS, defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1 (NCT01958021)
Timeframe: Up to approximately 20 months
| Intervention | months (Median) |
|---|---|
| LEE011 + Letrozole | NA |
| Placebo + Letrozole | 14.7 |
Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy. Pathologic complete response: no invasive cancer in the residual breast. Near pathologic complete response: residual disease of less than 1 cm in breast. (NCT00548184)
Timeframe: 12 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Pathologic Response | Near Complete Pathologic Response | Not Pathologic response | |
| Lapatinib + Trastuzumab | 18 | 16 | 30 |
Clinical benefit rate will be estimated by the total number of patients with an objective status of CR, PR, or SD for duration of at least 6 months divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true clinical benefit rate will be calculated. (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II | 0 |
A confirmed response is defined to be a CR or PR (as determined by RECIST criteria) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response will be evaluated using all cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response. The number of confirmed responses will be reported here. (NCT01105312)
Timeframe: from baseline up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I: Dose Level One | 0 |
| Phase I: Dose Level Two | 2 |
Duration of response is defined for all evaluable patients who have achieved a confirmed response as the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented. The distribution of duration of response will be estimated using the method of Kaplan-Meier. (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | NA |
MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6> new patients). If dose-limiting toxicity (DLT) is not seen in any of the 3 patients, 3 new patients will be accrued and treated at the next higher dose level. If DLT are seen in 2 or 3 of 3 patients treated at a given dose level, then the next 3 patients will be treated at the next lower dose level, if only 3 patients were enrolled and treated at this lower dose level. The number of DLT's will be reported here. (NCT01105312)
Timeframe: Up to 2.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I: Dose Level One | 1 |
| Phase I: Dose Level Two | 3 |
Progression-free survival (PFS) is defined as the time from registration to progression or death due to any cause. PFS at 6 months will be estimated. The distribution of PFS will be estimated using the method of Kaplan-Meier. (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | months (Median) |
|---|---|
| Phase II | 2.1 |
"A confirmed response is defined to be a CR or PR (as determined by RECIST (version 1.1 criteria) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response will be evaluated using all cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.~A CR is defined as:~All of the following must be true:~Disappearance of all non-nodal target lesions~Each target lymph node must have reduction in short axis to <1.0 cm~A PR is defined as:~At least a 30% decrease in the sum of the longest diameters of the non-nodal target lesions and the short axes of the target lymph nodes taking as reference the BSD (Section 11.41)" (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II | 0 |
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | 16.1 |
Time to treatment failure (TTF) is defined as the time from the date of registration to the date at which the patient is removed from treatment due to progression, unacceptable adverse events, or refusal. The distribution of TTF will be estimated using the method of Kaplan-Meier (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | 2 |
"Time-to-disease progression (TTP) is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. The distribution of TTP will be estimated using the method of Kaplan-Meier. Progression is defined as at least one of the following:~At least one new malignant lesion or a lymph node whose short axis has increased to >1.5 cm~At least a 20% increase in the sum of diameters of target lesions taking as reference the MSD. In addition, the sum must also demonstrate an absolute increase of at least 0.5 cm" (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | months (Median) |
|---|---|
| Phase II | 2.1 |
4 reviews available for letrozole and Lymph Node Metastasis
| Article | Year |
|---|---|
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2008 |
Overcoming recurrence risk: extended adjuvant endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2008 |
Collision of three histologically distinct endometrial cancers of the uterus.
Topics: Aged; Aromatase Inhibitors; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Pap | 2012 |
Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cli | 2006 |
11 trials available for letrozole and Lymph Node Metastasis
| Article | Year |
|---|---|
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, A | 2017 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Sc | 2019 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2016 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase I | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase I | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase I | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase I | 2005 |
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozo | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, D | 2008 |
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chem | 2008 |
20 other studies available for letrozole and Lymph Node Metastasis
| Article | Year |
|---|---|
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Topics: Adult; Aged; Breast Neoplasms; Estrogen Receptor alpha; Female; Humans; Letrozole; Lymphatic Metasta | 2021 |
Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; | 2021 |
Long-term response on letrozole for gastric cancer: A case report.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Fatal Outcome; Female; H | 2021 |
Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report.
Topics: Aromatase Inhibitors; Blood Coagulation Disorders; Bone Neoplasms; Carcinosarcoma; Female; Humans; L | 2017 |
Late distant recurrence of breast carcinoma and metastasis to the main bronchus and choroid: A case report.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Bronchi; Bronchial Neoplasms; | 2018 |
Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cohort St | 2018 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Ne | 2015 |
Is there a role for hormonal therapy in neuroendocrine carcinoma of the breast? A Paradigmatic case report.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocr | 2014 |
Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvan | 2016 |
Evaluating Markers for Guiding Treatment.
Topics: Age Factors; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; | 2016 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
[Endobronchial metastases from breast cancer: a clinicopathological and survival analysis].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Ductal, Breast; Chem | 2012 |
Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuva | 2003 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; | 2006 |
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2006 |
Aromatase inhibitors and male breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Br | 2007 |
Excellent response to letrozole in brain metastases from breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Cranial Irrad | 2008 |